MetaCap

Veradermics Incorporated (MANE)

NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

119.52-4.87 (-3.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MANE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.89
52-week range
32.00 – 156.63
Day range
118.99 – 123.70
Volume / Avg
374.92K / 738.22K
Beta
—

52-week range

$32.00$156.63

MANE stock today

Veradermics (MANE) closed at $119.52 on Nov 20, down 3.92% (-$4.87), versus the S&P 500's 3.70% decline. Shares are 23.7% below their 52-week high of $156.63, set on Nov 11, 2026 and 273.5% above the 52-week low of $32.00, in the middle of the past year's range. Veradermics has posted a net loss over the last twelve months (EPS of -$3.89), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Veradermics

Company profile

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Reid Waldman M.D.
Headquarters
New Haven, CT
Employees
51
IPO year
2026

Financial highlights

Full financials

Veradermics reported a net loss of $70.0 million, compared with a loss of $26.5 million a year earlier. Diluted earnings per share came in at -$111.91.

Veradermics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-70.00M$-26.49M
EPS (diluted)$-111.91$-37.05

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$187.33+56.74%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $172.00High $204.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.50 vs $-0.59
Surprise
+15.25%

MANE news

All MANE news

Veradermics peers

Health Care sector
MANE peer companies
CompanyPrice% ChgMarket capCompare
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs MANE
LQDALiquidia Corporation54.43-3.88%$4.90Bvs MANE
ERASErasca Inc.13.61-4.29%$4.78Bvs MANE
DNTHDianthus Therapeutics Inc.84.55-0.33%$4.76Bvs MANE
PTCTPTC Therapeutics Inc.56.42-3.27%$4.71Bvs MANE
COGTCogent Biosciences Inc.26.72-3.69%$4.65Bvs MANE
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs MANE
TVTXTravere Therapeutics Inc.47.00-2.69%$4.51Bvs MANE

Indexes, lists and sector

Veradermics stock FAQ

What is Veradermics's stock price today?

MANE last traded at $119.52 as of Nov 20, 4:00 PM EST, down 3.92% on the day. Prices are delayed at least 15 minutes.

Who is Veradermics's CEO?

Dr. Reid Waldman M.D. is the chief executive officer of Veradermics Incorporated, which has about 51 employees.

What is the MANE 52-week high?

The 52-week high for MANE is $156.63 and the 52-week low is $32.00. The stock is currently 23.7% below its high.

Compare MANE